The experimental weight-loss drug, currently being developed by Eli Lilly and Company, has generated widespread excitement following clinical trial results showing participants lost an average of 28% of their body weight over 80 weeks at the highest dose studied
The STEP trials for semaglutide 2.4 mg (Wegovy) showed: Average weight loss of approximately 15% of body weight over 68 weeks One-third of participants lost 20% or more of body weight Significant reductions in waist circumference, blood pressure, and cardiovascular risk markers The SURMOUNT trials for tirzepatide (Zepbound) showed even more impressive results: Average weight loss of 20-25% at the highest dose (15 mg) over 72 weeks More than half of participants lost 20% or more of body weight Significant improvements in type 2 diabetes markers, blood pressure, and lipid profiles The head-to-head comparison is clear
Bath & Body Works Champagne Toast Lip Oil Current price: $12.95 From Bath & Body Works Loading Inventory
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al
Many patients report experiencing fewer illnesses and faster recovery times